Investors & Media

  • Webcast
    18th Annual Needham Healthcare Conference
    04/09/19 12:50 pm EDT

Company Profile

As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. Our sights are set on all the patients we have yet to reach with a pipeline of more than 40 novel medicines designed to treat a broad range of diseases including cardiovascular diseases, neurological diseases, infectious diseases, pulmonary diseases and cancer.

To learn more about Ionis follow us on twitter @ionispharma.

Recent Press Releases

More >>
Date Title and Summary
Toggle Summary Ionis Pharmaceuticals to provide corporate update at 2019 Annual Meeting of Stockholders
CARLSBAD, Calif. , April 8, 2019 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present a general corporate update in conjunction with its 2019 Annual Meeting of Stockholders and Open House on Thursday, June 6 at 2:10 p.m. Pacific Time ( 5:10 p.m.
Toggle Summary Ionis announces appointment of Brett P. Monia Ph.D. to its board of directors
CARLSBAD, Calif. , March 25, 2019 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, today announced that Brett P. Monia , Ph.D., has been appointed to the company's board of directors. Dr. Monia currently serves as Ionis' chief operating officer
Toggle Summary Akcea and Ionis announce upcoming data presentations at the 2019 American College of Cardiology Meeting (ACC.19)
Presentations focus on the benefits of treatment with TEGSEDI™ (inotersen) and results show continued efficacy with long-term exposure in the NEURO-TTR open-label extension study BOSTON and CARLSBAD, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc.
Toggle Summary Ionis Pharmaceuticals to present at upcoming investor conferences
CARLSBAD, Calif. , March 7, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences: Cowen 39 th Annual Health Care Conference on Wednesday, March 13,

Upcoming Events

More >>
Date Event Details
Summary Toggle 06/06/19 5:10 pm EDT
Summary Toggle 06/15/19 12:15 pm CEST - 1:45 pm CEST

Register Here: http://www.cvent.com/d/x6q9l1

 

Bridging the Gap

 

Location:
European Society of Human Genetics Annual Conference 
Swedish Exhibition & Congress Center
Mässans Gata/Korsvägen
412 94 Göteborg, Sweden
 

  • Registration for the ESHG conference is required
  • First 50 registrants receive a free gift
  • Lunch will be provided

Location

European Society of Human Genetics Annual Conference

For more information requests, please visit our Information Request page.

If you are interested in Ionis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.

Copyright West LLC. Minimum 15 minutes delayed.

©1999 - 2017 Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals, Inc.